Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 162

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity

Open access
Heitzeneder, Sabine, Bosse, Kristopher R., Zhu, Zhongyu, Zhelev, Doncho, Majzner, Robbie G., Radosevich, Molly T., Dhingra, Shaurya, Sotillo, Elena, Buongervino, Samantha, Pascual-Pasto, Guillem, Garrigan, Emily, Xu, Peng, Huang, Jing, Salzer, Benjamin, Delaidelli, Alberto, Raman, Swetha, Cui, Hong, Martinez, Benjamin, Bornheimer, Scott J., Sahaf, Bita, Alag, Anya, Fetahu, Irfete S., Hasselblatt, Martin, Parker, Kevin R., Anbunathan, Hima, Hwang, Jennifer, Huang, Min, Sakamoto, Kathleen, Lacayo, Norman J., Klysz, Dorota D., Theruvath, Johanna, Vilches-Moure, José G., Satpathy, Ansuman T., Chang, Howard Y., Lehner, Manfred, Taschner-Mandl, Sabine, Julien, Jean-Phillipe, Sorensen, Poul H., Dimitrov, Dimiter S., Maris, John M., Mackall, Crystal L. · 2022 · Cancer Cell

Abstract

Pediatric cancers often mimic fetal tissues and express proteins normally silenced postnatally that could serve as immune targets. We developed T cells expressing chimeric antigen receptors (CARs) targeting glypican-2 (GPC2), a fetal antigen expressed on neuroblastoma (NB) and several other solid tumors. CARs engineered using standard designs control NBs with transgenic GPC2 overexpression, but not those expressing clinically relevant GPC2 site density (∼5,000 molecules/cell, range 1–6 × 10 3 ). Iterative engineering of transmembrane (TM) and co-stimulatory domains plus overexpression of c-Jun lowered the GPC2-CAR antigen density threshold, enabling potent and durable eradication of NBs expressing clinically relevant GPC2 antigen density, without toxicity. These studies highlight the critical interplay between CAR design and antigen density threshold, demonstrate potent efficacy and safety of a lead GPC2-CAR candidate suitable for clinical testing, and credential oncofetal antigens as a promising class of targets for CAR T cell therapy of solid tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ccell.2021.12.005

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

Metadata

Authors
Heitzeneder, S., Bosse, K. R., Zhu, Z., Zhelev, D., Majzner, R. G., Radosevich, M. T., Dhingra, S., Sotillo, E., Buongervino, S., Pascual-Pasto, G., Garrigan, E., Xu, P., Huang, J., Salzer, B., Delaidelli, A., Raman, S., Cui, H., Martinez, B., Bornheimer, S. J., Sahaf, B., Alag, A., Fetahu, I. S., Hasselblatt, M., Parker, K. R., Anbunathan, H., Hwang, J., Huang, M., Sakamoto, K., Lacayo, N. J., Klysz, D. D., Theruvath, J., Vilches-Moure, J. G., Satpathy, A. T., Chang, H. Y., Lehner, M., Taschner-Mandl, S., Julien, J.-P., Sorensen, P. H., Dimitrov, D. S., Maris, J. M., & Mackall, C. L.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2022-01
Volume
40
Issue
1
Pages
53-69.e9
ISSN
1535-6108 (ISSN-L)
OpenAlex
W4200349633
Cited by
162
References
8
FWCI
7.83
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.